Skip to main content
Premium Trial:

Request an Annual Quote

Genome Canada Launches National Precision Medicine Initiative

NEW YORK (GenomeWeb) – Genome Canada announced today that it has launched a national initiative to promote the clinical implementation of precision medicine, with an initial focus on rare diseases.

Genome Canada is aiming to build a national rare disease cohort by collecting and sequencing 30,000 samples from patients with rare diseases as well as  their families. The organization will also help create a platform to provide mechanisms and best practices for responsible data collection and sharing, and will work with provincial and regional collaborators to establish clinical sites, and to achieve regulatory approval and accreditation.

Genome Canada said it has established an advisory committee that includes rare disease researchers, clinicians, patient advocates, and policy and ethics experts to help guide the initiative.

"The launch of this strategy is a major step towards implementing precision health into Canada's healthcare system," Genome Canada President and CEO Marc LePage said in a statement. "We look forward to engaging patients, the provinces, healthcare providers, and researchers in this exciting and important initiative."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.